Industry News

Incyte’ s IDO1 inhibitor in combination with Merck’ s anti-PD-1 therapy is well-tolerated and demonstrates durable clinical response in patients with treatment-naïve advanced melanoma. WILMINGTON, Del.---- Incyte Corporation today announced that the European Society for Medical Oncology has published an abstract containing updated data from the Phase 1 portion of the ECHO-202 trial evaluating the safety and efficacy of epacadostat, Incyte’ s selective IDO1 enzyme..."/>
Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda® (Pembrolizumab)
EnteroMedics Inc reported on Tuesday the addition of Dan Gladney as chairman of the board of directors. Effective 14 October 2016, Gladney will succeed the company's co-founder, Dr Mark Knudson, who will be retiring from the board. However, Dr Knudson will be special advisor to the CEO on clinical and scientific activities following his retirement."/>
EnteroMedics elects Dan Gladney as board chair
Medivation, Inc. today announced that new data from Company-sponsored and investigator-initiated clinical trials will be presented at the European Society for Medical Oncology 2016 Congress, being held October 7-11, in Copenhagen. Presentations include a pilot study of the company's investigational PARP inhibitor talazoparib in patients with BRCA-mutated breast cancer, and analyses of enzalutamide in the advanced prostate cancer setting,..."/>
Medivation Highlights New Data From Differentiated Oncology Portfolio at ESMO 2016
Ensign Group, Inc., the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, hospice care, assisted living and urgent care companies, today announced that its urgent care subsidiary, Immediate Clinic Seattle, Inc., agreed to terms to sell substantially all of its assets relating to its 14 urgent care operations in the greater Seattle market.. The buyer, MultiCare Health System, is a not-for-profit health care..."/>
The Ensign Group Agrees to Sell Its Urgent Care Operations
IsoRay, Inc., a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the launch of its newly redesigned corporate website at The redesigned website introduces IsoRay's new branding and logo and offers quick and easy access to essential information that provides a..."/>
IsoRay, Inc. Announces Launch of Newly Redesigned Patient and Clinician Focused Corporate Website
Exact Sciences Corp. today announced that the company will host a webcast and conference call on Oct. 26, 2016, to discuss its third-quarter 2016 financial results. Third-Quarter 2016 Webcast and Conference Call Details. An archive of the webcast will be available at"/>
Exact Sciences to host third-quarter 2016 results webcast and call
Pfizer Inc. today announced that it will be presenting data from 20 abstracts, including three late-breakers, at the European Society for Medical Oncology 2016 Congress in Copenhagen from October 7-11,..."/>
Pfizer to Showcase Progress of Broad-Based Oncology Portfolio at European Society for Medical Oncology (ESMO) 2016 Congress
Centene's campus expansion Tuesday night, clearing the biggest hurdle to the health care company's plans to bring another 2,000 employees to downtown Clayton. The unanimous vote caps months of review before the city's plan commission. Many residents had expressed concern the huge campus along Forsyth Boulevard was too much too fast and would clog Clayton's streets with traffic."/>
Clayton approves Centene rezoning [St. Louis Post-Dispatch]
Boston Herald The Ticker column [Boston Herald]
GUERBET : 2016 half-year results
EndoChoice, which markets a variety of gastrointestinal endoscopy products, headed by the Full Spectrum Endoscope, a unique Israeli-developed colonscope, today announced that it would be acquired by Boston Scientific for $210 million. EndoChoice is listed on Nasdaq at a $109 million market cap, meaning that the acquisition is at a premium of almost 100%. EndoChoice held its IPO in 2015, raising $96 million at a company value of $366 million, after money, and reached a peak..."/>
Boston Scientific buys EndoChoice for $210m [Globes, Tel Aviv, Israel]
Sanomedics, by lying that former Apple and Pepsi CEO John Sculley, Miami-based IVAX Corp. Chairman Phillip Frost and "Dog Whisperer" Cesar Millan were big investors or representatives,..."/>
FBI busts Miami Lakes boiler room operators in alleged $23 million scam [The Miami Herald]
Boston Scientific Corp. on Tuesday announced plans for a $210 million acquisition that would broaden the medical technology company's line of products for diagnosis and treatment of gastrointestinal conditions like colon cancer. Massachusetts-based Boston Scientific, which derives two-thirds of its revenue from divisions based in Minnesota, said it will acquire all the stock of EndoChoice Holdings in Alpharetta, Ga. The deal is expected to close by the end of the..."/>
Boston Scientific will pay $210M for endoscopy maker EndoChoice [Star Tribune (Minneapolis)]
Stereotaxis said Tuesday that it had made strategic changes that include securing a large equity investment and making key board appointments. The moves "should provide us with the opportunity to achieve profitability," Stereotaxis CEO William C. Mills said in a statement. Louis-based company that makes computerized systems to treat heart arrhythmias said it secured a $24 million equity investment from..."/>
Stereotaxis announces new investors, board members [St. Louis Post-Dispatch]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology544 Articles
Consumer Discretionary483 Articles
Financials312 Articles
Industrials304 Articles
Health Care270 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at